ENTX Valuation

Entera Bio Ltd

Add to Watchlist

Advanced Chart

1.860

-0.05(-2.618%)1D

Overview
Forecast
Valuation
Earnings

ENTX Relative Valuation

ENTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENTX is overvalued; if below, it's undervalued.

Historical Valuation

Entera Bio Ltd (ENTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -3.98. The fair price of Entera Bio Ltd (ENTX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.91 USD , Entera Bio Ltd is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：1.91

Fair

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.48

P/B

Median3y

5.23

Median5y

5.18

-7.26

FCF Yield

Median3y

-26.50

Median5y

-25.32

Competitors Valuation Multiple

The average P/S ratio for ENTX's competitors is 9.29, providing a benchmark for relative valuation. Entera Bio Ltd Corp (ENTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap